Kanaly Trust’s Enanta Pharmaceuticals ENTA Stock Holding History

Kanaly Trust’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-45	Closed	-$2K	–	744
2014 Q3	$2K	Buy	+45	New	+$1.79K	﹤0.01%	701

Other funds holding ENTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kanaly Trust's ENTA Position: Q4 2014 in Review

Kanaly Trust sold out of Enanta Pharmaceuticals (ENTA) in Q4 2014, closing a stake of 45 shares — an estimated $2K sold.

Kanaly Trust first reported a position in ENTA in Q3 2014 and held it in 1 quarter. The position peaked at $2K in Q3 2014. 124 funds tracked by Wall St. Rank hold ENTA as of Q4 2014.

Kanaly Trust reported no remaining Enanta Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Kanaly Trust sold 45 Enanta Pharmaceuticals shares in Q4 2014, an estimated $2K.
Kanaly Trust first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 1 quarter.
Kanaly Trust's Enanta Pharmaceuticals position peaked at $2K in Q3 2014.
124 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2014.

Based on Kanaly Trust's 13F filing for Q4 2014, filed 26 Jan 2015.